Press release
Pheochromocytoma Market to Reach USD 334 Million by 2034
Pheochromocytoma Market
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71562
Key Takeaways
• Market Size (2024): USD 205 Million
• Forecast (2034): USD 334 Million
• CAGR (2025-2034): 5.0%
• Growth Drivers: Early genetic screening, precision radiotherapy development, and wider availability of molecular diagnostic tools.
• Leading Players: Novartis AG, Pfizer Inc., Bristol Myers Squibb, GE HealthCare Technologies Inc., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and Mayo Clinic Laboratories.
Market Story
Pheochromocytoma is a rare neuroendocrine tumor arising from the adrenal medulla, often associated with excessive catecholamine production, hypertension, and hereditary syndromes such as MEN2 and VHL. Early detection is critical to avoid cardiovascular complications and metastasis.
Recent advances in genetic testing, molecular diagnostics, and radiopharmaceutical imaging are transforming disease management. Tools such as metaiodobenzylguanidine (MIBG) scintigraphy, PET/CT imaging with 68Ga-DOTATATE, and next-generation sequencing (NGS) enable precise diagnosis and classification of tumors.
On the therapeutic side, targeted alpha-particle therapy (TAT), radio-labeled peptide therapies, and selective tyrosine kinase inhibitors (TKIs) are gaining prominence for metastatic and recurrent cases. The growing use of AI-based diagnostic imaging and bioinformatics-driven gene mutation analysis is improving early diagnosis and personalized treatment outcomes.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71562/pheochromocytoma-market
Market Segmentation
By Diagnostic Type:
• Biochemical Testing (Plasma Free Metanephrines, Urinary Metanephrines)
• Imaging Tests (CT, MRI, PET, MIBG Scans)
• Genetic Testing
By Treatment Type:
• Surgical Therapy (Adrenalectomy)
• Chemotherapy
• Targeted Therapy
• Radiopharmaceutical Therapy
• Others
By End-User:
• Hospitals
• Diagnostic Laboratories
• Specialty Clinics
• Research Institutes
By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Recent Developments
• 2025: Novartis AG launched new clinical trials for radiolabeled therapies targeting pheochromocytoma and paraganglioma.
• 2024: GE HealthCare expanded its nuclear medicine portfolio with PET imaging tracers for neuroendocrine tumor visualization.
• 2024: Pfizer collaborated with oncology centers to research TKI combinations for rare adrenal malignancies.
• 2023: Thermo Fisher Scientific introduced comprehensive NGS panels for hereditary pheochromocytoma risk screening.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71562
Expert Insight
"Advancements in molecular imaging, genomics, and precision oncology are transforming how rare tumors like pheochromocytoma are managed," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
"The future of adrenal tumor diagnosis lies in integrating genetic, biochemical, and imaging insights for truly personalized medicine."
Regional Outlook
• North America leads the market with over 40% share, driven by robust R&D funding, high awareness, and access to advanced imaging modalities.
• Europe continues to expand with strong diagnostic infrastructure and government-backed rare disease research programs.
• Asia Pacific is projected to grow at 6.2% CAGR, led by improving diagnostic access in China, India, and Japan.
• Latin America & Middle East are emerging markets with increasing adoption of nuclear medicine and endocrine screening programs.
Conclusion
The Pheochromocytoma Market is evolving rapidly with the convergence of genetic science, nuclear imaging, and targeted therapeutics. As precision medicine becomes central to rare disease management, early diagnosis and personalized therapy will drive improved survival rates and better quality of life for patients worldwide.
This report is also available in the following languages : Japanese (褐色細胞腫市場), Korean (갈색세포종 시장), Chinese (嗜铬细胞瘤市场), French (Marché du phéochromocytome), German (Phäochromozytom-Markt), and Italian (Mercato del feocromocitoma), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71562
Our More Reports:
Heart Failure Drugs Market
https://exactitudeconsultancy.com/reports/49895/heart-failure-drugs-market
Pharmacy Automation Market
https://exactitudeconsultancy.com/reports/49900/pharmacy-automation-market
Cardiac Mapping Market
https://exactitudeconsultancy.com/reports/49903/cardiac-mapping-market
Eye Health Supplements Market
https://exactitudeconsultancy.com/reports/49905/eye-health-supplements-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pheochromocytoma Market to Reach USD 334 Million by 2034 here
News-ID: 4266777 • Views: …
More Releases from Exactitude Consultancy
Cardiac Biomarkers Market to Reach USD 24.1 Billion by 2034
Pune, India, November 2025 - According to the latest report by Exactitude Consultancy, the Global Cardiac Biomarkers Market is valued at USD 14.9 billion in 2024 and is projected to reach USD 24.1 billion by 2034, growing at a CAGR of 5.0% from 2025 to 2034. Increasing global prevalence of cardiovascular diseases (CVDs), along with growing adoption of advanced diagnostic assays and AI-based cardiac risk prediction, is driving strong market…
Demerol (Meperidine) Market to Reach USD 1.27 Billion by 2034
Pune, India, November 11, 2025 - The global Demerol (Meperidine) Market is projected to grow from USD 870 million in 2024 to USD 1.27 billion by 2034, registering a CAGR of 3.9 %, according to Exactitude Consultancy. Rising surgical volumes, continued use of short-acting opioid analgesics, and structured opioid-stewardship frameworks in hospitals are sustaining global market demand while balancing safety and efficacy concerns.
Download Full PDF Sample Copy of Market Report…
Antibiotic Resistance Market to Surpass USD 18.9 Billion by 2034
Pune, India, November 2025 - According to a new report published by Exactitude Consultancy, the Global Antibiotic Resistance Market is valued at USD 12.5 billion in 2024 and is projected to reach USD 18.9 billion by 2034, growing at a CAGR of 4.2% from 2025 to 2034. The surge in multidrug-resistant infections, coupled with increasing R&D investment in next-generation antimicrobials and rapid diagnostic technologies, is driving sustained market growth worldwide.
Download…
Trenbolone Enanthate Market to Reach USD 92.3 Million by 2034
Pune, India, November 11, 2025 - The global Trenbolone Enanthate Market is projected to increase from USD 59.4 million in 2024 to USD 92.3 million by 2034, registering a CAGR of 4.5 %, according to Exactitude Consultancy. Rising meat consumption, growth in livestock-fattening programs, and the expanding use of veterinary performance-enhancing compounds are driving demand across both developed and emerging markets.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/50053
Key…
More Releases for Pheochromocytoma
Pheochromocytoma Market Emerging Trends and Growth Prospects 2034
Introduction
Pheochromocytoma is a rare tumor arising from adrenal gland chromaffin cells, often associated with excessive catecholamine secretion that leads to hypertension and cardiovascular complications. Although considered an orphan disease due to its rarity, pheochromocytoma has gained increasing medical and research attention over the past decade. Advancements in genetic testing, diagnostic imaging, and molecular therapies have opened new opportunities for more accurate detection and effective management.
The global Pheochromocytoma Market is entering…
Rising Tumor Incidence Rates Fueling Growth In The Pheochromocytoma Market Drivi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Pheochromocytoma Market Size By 2025?
The market size of pheochromocytoma has been on a steady upward trend over the past years. It is projected to increase from $3.03 billion in 2024 to $3.17 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 4.7%.…
Emerging Trends Influencing The Growth Of The Pheochromocytoma Market: Innovativ …
The Pheochromocytoma Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Pheochromocytoma Market Size Expected to Be by 2034?
The market size of pheochromocytoma has consistently expanded over the past few years. It's estimated to increase from $3.03 billion in 2024 to $3.17…
Top Factor Driving Pheochromocytoma Market Growth in 2025: Rising Tumor Incidenc …
How Big Is the Pheochromocytoma Market Expected to Be, and What Will Its Growth Rate Be?
The pheochromocytoma market has grown steadily in recent years. It will rise from $3.03 billion in 2024 to $3.17 billion in 2025, at a CAGR of 4.7%. This growth is attributed to increased healthcare spending, a rise in diagnoses and awareness, genetic research, and government initiatives.
The pheochromocytoma market is projected to see steady growth, reaching…
Pheochromocytoma Market Growth, Analysis And Forecast 2033
The new report published by The Business Research Company, titled Pheochromocytoma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the pheochromocytoma market size has grown steadily in recent years. It will grow from $2.89 billion in 2023 to $3.03…
Pheochromocytoma Market Size, Share, Growth Forecast 2030
Pheochromocytoma, a rare but formidable adrenal gland tumor, has sparked increased interest in the medical community due to its complex nature. This article delves into the competitive landscape, future growth prospects, opportunities, drivers, restraints, and major market players in the Pheochromocytoma market. Additionally, we will explore current market trends and regional insights, shedding light on the evolving landscape of this niche market.
Download Free Pheochromocytoma Market Sample Report Here: (Including Full…
